SOVREMENNAYA PEDIATRIYA.2016.5(77):62-66; doi10.15574/SP.2016.77.62 

Infection prevention in children with hereditary hemolytic anemia 

Oniskova O. V., Yushchenko L. O., Antonets V. A., Konoplitskaya A. P., Malanina T. L., Kovalchuk K. P.

Vinnytsya National Pyrogov Memorial Medical University, Ukraine

Vinnytsya Region Children Hospital, Ukraine

Hereditary hemolytic anemia (hereditary spherocytosis and elliptocytosis) are inherited red cell disorders caused by defects in various membrane proteins in North America and Europe. Treatment of these patients is based on periodical control and supply of information on the adequate management of hemolytic or aplastic crisis, and early detection of cholelithiasis. Splenectomy is curative but should be undertaken only after careful assessment of the risks and benefits. There is a significantly increased risk of severe postsplenectomy infection. The mainstays of prevention are immunization. In Vinnytsya region are registered 19 children with hereditary hemolytic anemia. Three patients (2 girls and 1 boy) with hereditary hemolytic anemia elliptocytosis were immunized in hospital during 2014–2015. We evaluated haematological and biochemical parameters after immunization. After immunization children had different changes of their condition that is why we recommend immunize children in the hospital.

Key words: children, hereditary hemolytic anemia, immunization.

REFERENCES

1. Babaev ES, Poddubnyiy IV. 2001. Novyiy podhod k lecheniyu nasledstvennogo sferotsitoza u detey. Gematologiya i transfuziologiya. 48;5: 18—21.

2. Babaev ES. 2001. O mehanizme razrusheniya eritrotsitov pri nasledstvennom sferotsitoze i podhodah k ustraneniyu patologicheskogo protsessa u detey. Gematologiya i transfuziologiya. 46;1: 34—37.

3. Babaev ES, Kulikov SV. 2002. Otdalennyie rezultatyi enovaskulyarnoy okklyuzii selezYonki u detey, bolnyih nasledstvennyim sferotsitozom. Gematologiya i transfuziologiya. 47; 6: 37—39.

4. Rumyantseva YuV, Firsov NN, Smetanina NS et al. 2003. Vliyanie splenektomii na reologicheskie svoystva krovi u bolnyih nasledstvennoy sferotsitarnoy gemoliticheskoy anemiey. Gematologiya i transfuziologiya. 14; 5: 28—33.

5. Lohmatova ME, Vinyarskaya IV, Finogenova NA et al. 2011. Kachestvo zhizni detey s raznyimi nasledstvennyimi gemoliticheskimi anemiyami. Rossiyskiy pediatrich zhurn. 1: 23-26.

6. Yevstakhevych II, Lohinskyi VIe, Leshchuk TV et al. 2008. Kliniko-hematolohichna klasyfikatsiia spadkovoho sferotsytozu i taktyka khirurhichnoho likuvannia. Ukrainskyi zhurn hematol ta transfuziol. 3(8): 15—19.

7. Kostyuchenko L.V. 2014. Prevention of infections in patients with asplenia or dysfunction of the spleen. Sovremennaya pediatriya. 7(63): 80—84. doi 10.15574/SP.2014.63.80

8. Smetanina NS, Firsov NN, Baydun LV et al. 2001. Morfologicheskie i biofizicheskie parametryi eritrotsitov u detey bolnyih β-talassemiey i nasledstvennyim sferotsitozom. Gematologiya i transfuziologiya. 48; 5: 16—18.

9. Pro udoskonalennia provedennia profilaktychnykh shcheplen v Ukraini. nakaz MOZ Ukrainy №551 vid 11.08.2014 r. http: //www.mouz.cv.ua /2014/11/24/nakaz-moz-ukrayini-vd-11082014-551-pro-udoskonalennya-provedennya-profilactichnih-scheplen-v-ukrayin. html.

10. Prohorova YuA, Zueva EE, Sokolova NE. 2012. Primenenie metoda protochnoy tsitometrii v diagnostike nasledstvennogo sferotsitoza. Klinicheskaya laboratornaya diagnostiki. 7: 31—35.

11. Polyaev YuYa, Gassan TA, Smetanina NS et al. 2008. Enovaskulyarnaya okklyuziya selezyonki u bolnyih nasledstvennoy sferotsitarnoy gemoliticheskoy anemiey i idiopaticheskoy trombotsitopenicheskoy purpuroy. Gematologiya i transfuziologiya. 53; 1: 5—11.

12. Eber SW, Belohradsky BH, Weiss M. 2001. Antiinfectious prophylaxis in asplenia. Klin Padiatr. 213; Suppl 1: 84—87. http://dx.doi.org/10.1055/s-2001-17504; PMid:11577367

13. Lazarova E, Pradier O, Cotton F, Gulbis B. 2014. Automated reticulocyte parameters for hereditary spherocytosis screening. Ann Hematol. 93; 11: 1809—1818. http://dx.doi.org/10.1007/s00277-014-2127-8; PMid:24912770

14. Castagnola E, Fioredda F. 2003. Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. Eur J Haematol. 71; 5: 319—326. http://dx.doi.org/10.1034/j.1600-0609.2003.00158.x; PMid:14667194

15. Dahyot-Fizelier C, Debaene B, Mimoz O. 2013. Management of infection risk in asplenic patients. Ann Fr Anesth Reanim. 32; 4: 251—256. http://dx.doi.org/10.1016/j.annfar.2013.01.025; PMid:23538102

16. Bolton-Maggs PH, Langer JC, Iolascon A et al. 2012. Guidelines for the diagnosis and management of hereditary spherocytosis — 2011 update. Br J Haematol. 156; 1: 37—49. http://dx.doi.org/10.1111/j.1365-2141.2011.08921.x; PMid:22055020

17. Perrotta S, Gallagher PG, Mohandas N. 2008. Hereditary spherocytosis. Lancet. 372; 9647: 1411—1426. http://dx.doi.org/10.1016/S0140-6736(08)61588-3

18. Das A, Bansal D, Das R et al. 2014. Hereditary spherocytosis in children: profile and post-splenectomy out-come. Indian Pediatr. 51; 2: 139—141. http://dx.doi.org/10.1007/s13312-014-0348-5; PMid:24632695

19. Da Costa L, Galimand J, Fenneteau O, Mohandas N. 2013. Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders. Blood Rev. 27; 4: 167—178. http://dx.doi.org/10.1016/j.blre.2013.04.003; PMid:23664421

20. Donato H, Crisp RL, Rapetti MC et al. 2015. Hereditary spherocytosis. Review. Part II. Symptomatology, outcome, complications, and treatment. Arch Argent Pediatr. 113; 2: 168—176. PMid:25727830

21. King MJ, Garcon L, Hoyer JD et al. 2015. ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders. Int J Lab Hematol. 37; 3: 304—325. http://dx.doi.org/10.1111/ijlh.12335; PMid:25790109

22. Coignard-Biehler H, Lanternier F, de Montalembert M et al. 2008. Infections in splenectomized patient. Rev Prat. 58; 20: 2209—2214. PMid:19209650

23. Jones P, Leder K, Woolley I et al. 2010. Postsplenectomy infection — strategies for prevention in general practice. Aust Fam Physician. 39; 6: 383—386. PMid:20628676

24. Teunissen M, Hijmans CT, Cnossen MH et al. 2014. Quality of life and behavioral functioning in Dutch pediatric patients with hereditary spherocytosis. Eur J Pediatr. 179; 9: 1217—1223. http://dx.doi.org/10.1007/s00431-014-2299-1; PMid:24737290

25. Roy SM, Buchanan GR, Crary SE. 2013. Splenectomy in children with «mild» hereditary spherocytosis. J Pediatr Hematol Oncol. 35; 6: 430—433. http://dx.doi.org/10.1097/MPH.0b013e31829f3460; PMid:23823113

26. Price VE, Dutta S, Blanchette VS et al. 2006. The prevention and treatment of bacterial infections in children with asplenia or hyposplenia: practice considerations at the Hospital for Sick Children, Toronto. Pediatr Blood Cancer. 46; 5: 597—603. http://dx.doi.org/10.1002/pbc.20477; PMid:16333816

27. Miniero R, Barretta M, Dolceamore TR et al. 2013. Update on prevention of infections in patients without spleen or with diminished splenic function. Minerva Pediatr. 65; 4: 427—445. PMid:24051976